9: Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM
(PubMed) If AOD-9604 re-enters mainstream clinical availability through compliant channels, the most responsible use-case will likely be: carefully selected patients, realistic expectations, body composition focus, and as an adjunctnot a centerpiece
If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the Report this comment function to alert our web team.
The exceptions: PT-141 for women uses 1.75 mg subcutaneously (the FDA-approved Vyleesi dose), which differs from the research doses listed for men
Quick Appointment Most appointments take approximately 15 minutes